A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers

NCT07580586 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Participants

Interventions

DRUG: BV100 (300 mg)
DRUG: Polymyxin B (50 mg)

Sponsor

BioVersys SAS